Cell cycle analysis of PBLs after infection with HIV-1 or MLV-derived vectors*
| Pseudotyped vector . | HIV-1† . | MLV† . |
|---|---|---|
| G | 1.4 | 0.2 |
| G + anti-CD3‡ | 1.3 | 0.8 |
| G + anti-CD3/anti-CD28‡ | 23 | 19 |
| G/OKT3SU | 9.5 | 6.5 |
| G/OKT3SUx | 8.7 | 12.5 |
| Pseudotyped vector . | HIV-1† . | MLV† . |
|---|---|---|
| G | 1.4 | 0.2 |
| G + anti-CD3‡ | 1.3 | 0.8 |
| G + anti-CD3/anti-CD28‡ | 23 | 19 |
| G/OKT3SU | 9.5 | 6.5 |
| G/OKT3SUx | 8.7 | 12.5 |
Percentage of cells in S/G2M phases of the cell cycle analyzed 6 days after infection. The data, shown here for PBLs of set 7 (Figures 5-8 present results of transduction), are representative of other experiments. Before infection, the proportion of cells in S/G2M for this particular batch of PBLs was 0.2%.
Type of vector used for PBL infection.
VSV-G–coated vectors used to infect nonactivated PBLs in the presence of 1 μg of the indicated antibodies.